Holen Sie sich die Stockscreener-App
0.9579
2.25%
0.0271
Handel nachbörslich:
.96
0.0021
+0.22%
Schlusskurs vom Vortag:
$0.9308
Offen:
$0.9985
24-Stunden-Volumen:
7.54M
Relative Volume:
1.90
Marktkapitalisierung:
$279.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-3.5478
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
+17.50%
1M Leistung:
+32.33%
6M Leistung:
-1.86%
1J Leistung:
-45.62%
1-Tages-Spanne:
$0.9284
$1.01
1-Wochen-Bereich:
$0.786
$1.01
52-Wochen-Spanne:
$0.515
$1.979
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9579 | 224.81M | 0 | -63.08M | -72.53M | -0.27 |
|
ONC
Beigene Ltd Adr
|
238.31 | 25.23B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.00 | 113.16B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 40.65M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.26 | 64.41B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.61 | 6.18B | 0 | -153.72M | -103.81M | -2.00 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals
Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com
Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - Seeking Alpha
FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com India
FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST--Modifier Gene Therapy for the Treatment of Stargardt Disease | OCGN Stock News - GuruFocus
FDA Grants Rare Pediatric Disease Designation to OCU410ST from Ocugen (OCGN) | OCGN Stock News - GuruFocus
Ocugen receives Rare Pediatric Disease Designation for OCU410ST - TipRanks
Ocugen Announces Rare Pediatric Disease Designation Granted - GlobeNewswire
FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood BlindnessNo Current Treatment Exists - Stock Titan
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Provides Business Update with First Quarter 2025 Financial Results - ADVFN
Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN
Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Canada
Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus
Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus
Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga
Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN
Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey
Ocugen: Q1 Earnings Snapshot - New Haven Register
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises By Investing.com - Investing.com India
Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
Earnings call transcript: Ocugen’s Q1 2025 loss narrows, stock rises - Investing.com
Ocugen’s Q1 2025: Progress in Gene Therapy Trials - TipRanks
Ocugen Inc’s Earnings Call: Optimism Amid Financial Challenges - TipRanks
Ocugen Provides Business Update with First Quarter 2025 Financia - GuruFocus
Ocugen Q1 2025 Earnings Call Transcript - MarketBeat
Ocugen (OCGN) Reveals Strong Q1 Revenue Growth and Strategic Cli - GuruFocus
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish By Stocktwits - Investing.com India
Ocugen (OCGN) Reveals Strong Q1 Revenue Growth and Strategic Clinical Advancements | OCGN Stock News - GuruFocus
Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Ex - GuruFocus
A Look at Ocugen's Upcoming Earnings Report - Nasdaq
Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Expectations - GuruFocus
Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock - Capital.com
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ocugen Inc-Aktie (OCGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
0.00%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):